Gamida Cell Reports First Quarter 2019 Financial Results and Provides Company Update
– Announces USAN selection of omidubicel as nonproprietary name for company’s investigational NAM-expanded hematopoietic stem cells (formerly known as NiCord®) –
– Patient enrollment in Phase 3 study of omidubicelexpected to be completed in second half of 2019; Topline results expected in first half of 2020 –
– Phase 1 clinical study of GDA-201 (formerly known as NAM-NK) continues to progress, with additional data expected in 2H19 –
“Gamida Cell is focused on transforming the treatment landscape for
patients with blood cancers and rare, serious hematologic diseases. We
are pleased that omidubicel has been selected as the nonproprietary name
for NiCord, highlighting our progress toward bringing this important
cell therapy to patients in need of a bone marrow transplant,” stated
Dr. Adams continued, “We are pleased that the multi-center, randomized Phase 3 study of omidubicel is progressing, with patient enrollment expected to be complete by the end of this year and topline data anticipated in the first half of 2020. Positive data from the study would enable the submission of our first biologics license application next year, which would be a significant achievement.”
“Earlier this year, we also reported encouraging data from the Phase 1 clinical study of our natural killer cell product candidate, GDA-201, previously known as NAM-NK. The multiple complete responses observed emboldened us to begin scaling up our manufacturing process to enable the evaluation of a cryopreserved formulation of GDA-201 in a multi-center, multi-dose Phase 1/2 clinical study in patients with non-Hodgkin lymphoma next year,” Dr. Adams concluded.
Company Highlights
- Omidubicel selected as nonproprietary name for NiCord: Today
Gamida Cell announced that theUnited States Adopted Names (USAN) Council selected omidubicel as the nonproprietary name for Gamida Cell’s investigational hematopoietic stem cell expanded through the company’s proprietary nicotinamide-based, or NAM, technology.The USAN Council aims for global standardization and unification of drug nomenclature to ensure that drug information is communicated accurately and unambiguously. Gamida Cell’s lead investigational product has two components: omidubicel (hematopoietic stem cells expanded through the company’s proprietary nicotinamide-based, or NAM, technology) and differentiated immune cells, including T cells.Gamida Cell refers to the two components collectively as “omidubicel.”Going forward,Gamida Cell will use the name “omidubicel” in publications and public statements, at conferences and other forums, and in medical and commercial-related materials. - Reported encouraging data for omidubicel and GDA-201 at TCT Annual
Meeting: In February, data from the omidubicel and GDA-201
clinical programs were reported at the 2019 Transplantation & Cellular
Therapy (TCT) Meetings of
American Society for Blood and Marrow Transplantation andCenter for International Blood and Marrow Transplant . Research from the completed Phase 1/2 clinical study of omidubicel demonstrated that recipients who received omidubicel had rapid and robust reconstitution of key immune cells. Successful immune reconstitution is an important factor in the recovery of patients undergoing bone marrow transplant.
Data were also reported from the ongoing Phase 1/2 study of omidubicel in patients with severe aplastic anemia. In the initial cohort of three patients, all successfully underwent a bone marrow transplant consisting of omidubicel plus a haploidentical stem cell graft. The results enable the initiation of a second cohort of patients to be treated with omidubicel as a stand-alone graft.Patient enrollment in the second cohort is expected to begin in the first half of 2019.
Additionally, data reported from the ongoing Phase 1 study of GDA-201 in patients with non-Hodgkin lymphoma (NHL ) and multiple myeloma (MM) demonstrated that GDA-201 was clinically active, with three complete responses observed in patients withNHL and one complete response in a patient with MM. These data, along with safety data showing that GDA-201 was generally well tolerated, support continued clinical development.Gamida Cell is planning to initiate a multi-center, Phase 1/2 clinical study of GDA-201 in patients withNHL in 2020.
- Evolved Board of Directors to reflect company’s progress toward
commercialization: In March,the company announced the
nominations of
Shawn Cline Tomasello andStephen T. Wills to its board of directors. These nominations require approval at the Annual Shareholders Meeting, which will take place inJune 2019 . Ms. Tomasello has extensive experience in commercializing first-in-class medicines for the treatment of cancer, including Yescarta® (at Kite Pharma, now part ofGilead Sciences ) and Imbruvica® (at Pharmacyclics, now part ofAbbVie ). Mr. Wills has extensive operational, financial and transactional experience over nearly three decades in the life sciences and accounting industries. He has served as chief financial officer ofPalatin Technologies , a publicly-traded biotechnology company developing peptide therapeutics, since 1997 and also serves as Palatin’s chief operating officer and executive vice president.
In January, the company appointedNurit Benjamini to Gamida Cell’s board of directors and chair of the board’s audit committee. Ms. Benjamini has served as chief financial officer ofTabTale Ltd. since 2013. Previously, she held a number of chief financial officer positions, including atWix.com Ltd. ,Sigma Designs Israel Ltd. andCompugen Ltd.
- Appointed
Thomas Klima as chief commercial officer: In January, the company announced the appointment ofThomas Klima as chief commercial officer.In this newly created role, Mr. Klima will be responsible for building the team and executing the strategy to potentially bring omidubicel to patients, including oversight of reimbursement and patient services.Klima brings nearly 20 years of global experience in the pharmaceutical industry with expertise in cellular therapy, hematology, oncology and transplantation. During his career, he has played key roles in building commercial organizations and leading multiple successful product launches.
Anticipated 2019-2020 Milestones
Gamida Cell’s anticipated
program milestones in 2019-2020 are as follows:
Omidubicel
- Initiate Cohort 2 in the Phase 1/2 study evaluating omidubicel as stand-alone graft in severe aplastic anemia in the first half of 2019
- Complete enrollment in Phase 3 study of omidubicel in patients with hematologic malignancies in the second half of 2019
- Report topline data from the Phase 3 study of omidubicel in patients with hematologic malignancies in the first half of 2020
- Complete BLA submission for omidubicel in hematologic malignancies in the second half of 2020, should Phase 3 data be positive
GDA-201
- Complete patient enrollment in the ongoing Phase 1 study in the second half of 2019
- Present additional data at a medical meeting in the second half of 2019
-
Initiate multi-center, Phase 1/2 clinical study in patients with
NHL in 2020
First Quarter 2019 Financial Results
-
As of
March 31, 2019 ,Gamida Cell had total cash, cash equivalents and available-for-sale securities of$50.3 million , compared to$60.7 million as ofDecember 31, 2018 . -
Research and development expenses in the first quarter of 2019 were
$7.3 million , compared to$5.1 million in the same period in 2018. The difference was attributable mainly to a$1.2 million increase in clinical activities relate to the advancement of omidubicel and GDA-201,$0.5 million reduction in grants received from theIsraeli Innovation Authority (IIA) and an increase of$0.5 million in compensation and other R&D expenses. -
General and administrative expenses were
$3.8 million for the first quarter of 2019, compared to$1.7 million in the same period in 2018. The increase was due mainly to a$1.0 million increase in expenses related to hiring and establishing the U.S. headquarters, an increase of$0.5 million in non-cash stock-based compensation expenses, and$0.6 million in professional services, rent and other expenses. -
Finance expenses, net, were
$4.4 million for the three months endedMarch 31, 2019 , compared to$0.7 million in income in the same period in 2018. The increase was primarily due to noncash expenses resulting from revaluation of warrants and the revaluation of royalty-bearing grant IIA liability. -
Net loss for the first quarter of 2019 was
$15.5 million , compared to a net loss of$7.4 million in the same period in 2018.
2019 Financial Guidance
Conference Call Information
About Omidubicel
Omidubicel (formerly known as NiCord®),
the company’s lead clinical program, is an advanced cell therapy under
development as a potential life-saving allogeneic hematopoietic stem
cell (bone marrow) transplant solution for patients with hematologic
malignancies (blood cancers).1 Omidubicel is the first bone
marrow transplant product to receive Breakthrough Therapy Designation
from the
About GDA-201
Omidubicel and GDA-201 are investigational therapies, and their
safety and efficacy have not been evaluated by the
About
Cautionary Note Regarding Forward Looking Statements
This
press release contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995,
including with respect to the patient enrollment in and timing of
initiation and progress of and data reported from the clinical trials of
Gamida Cell’s product candidates, and Gamida Cell’s expectations
regarding its projected operating expenses and cash runway, which
statements are subject to a number of risks, uncertainties and
assumptions, including, but not limited to the scope, progress and
expansion of Gamida Cell’s clinical trials and variability, and
ramifications for the cost thereof; and clinical, scientific, regulatory
and technical developments. In light of these risks and uncertainties,
and other risks and uncertainties that are described in the Risk Factors
section of Gamida Cell’s public filing on Form 20-F, filed with the
INTERIM CONSOLIDATEDSTATEMENTS OF FINANCIAL POSITION | ||||||||||
U.S. dollars in thousands | ||||||||||
March 31, | December 31, | |||||||||
2019 | 2018 | |||||||||
ASSETS |
||||||||||
CURRENT ASSETS: |
||||||||||
Cash and cash equivalents | $ | 43,749 | $ | 40,272 | ||||||
Available-for-sale financial assets | 6,507 | 20,417 | ||||||||
Prepaid expenses and other current assets | 684 | 1,502 | ||||||||
Totalcurrent assets |
50,940 | 62,191 | ||||||||
NON-CURRENT ASSETS: |
||||||||||
Property and equipment, net | 2,782 | 2,311 | ||||||||
Right-of-use assets | 6,668 | - | ||||||||
Other assets | 657 | 662 | ||||||||
Totalnon-current assets |
10,107 | 2,973 | ||||||||
Total assets |
$ | 61,047 | $ | 65,164 | ||||||
LIABILITIES AND EQUITY |
||||||||||
CURRENT LIABILITIES: |
||||||||||
Trade payables | $ | 1,341 | $ | 1,985 | ||||||
Employees and payroll accruals | 2,580 | 2,888 | ||||||||
Current maturities of lease liabilities | 2,156 | - | ||||||||
Accrued expenses and other payables | 1,739 | 1,832 | ||||||||
Total current liabilities |
7,816 | 6,705 | ||||||||
NON-CURRENT LIABILITIES: |
||||||||||
Liabilities presented at fair value | 25,031 | 24,049 | ||||||||
Employee benefit liabilities, net | 276 | 183 | ||||||||
Lease Liabilities | 4,671 | - | ||||||||
Liability to Israel Innovation Authority (IIA) | 10,108 | 9,540 | ||||||||
Total non-current liabilities |
40,086 | 33,772 | ||||||||
SHAREHOLDERS' EQUITY: |
||||||||||
Share capital | 68 | 67 | ||||||||
Share premium | 197,967 | 193,953 | ||||||||
Capital reserve due to actuarial gains | (160) | (77) | ||||||||
Available-for-sale reserve | (10) | (43) | ||||||||
Accumulated deficit | (184,720) | (169,213) | ||||||||
Total shareholders' equity |
13,145 | 24,687 | ||||||||
Total liabilities and shareholders' equity |
$ | 61,047 | $ | 65,164 |
1 Gamida Cell’s lead development candidate consists of
omidubicel (expanded hematopoietic stem cells) and differentiated immune
cells, including T cells.
2 Horwitz M.E., Wease S., Blackwell B., Valcarcel D. et al. Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide. J Clin Oncol. 2019 Feb 10;37(5):367-374.
3 ClinicalTrials.gov identifier NCT02730299.
4 ClinicalTrials.gov identifier NCT03173937.
5 ClinicalTrials.gov identifier NCT03019666.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190507005128/en/
Source:
Jaren Irene Madden
jaren@gamida-cell.com
617-892-9084
Krystle Gibbs (media)
krystle@tenbridgecommunications.com
508-479-6358